ES2060621T3 - Anticuerpos anti-sustancia fr-900506 y metodo de inmunoensayo enzimatico altamente sensible. - Google Patents

Anticuerpos anti-sustancia fr-900506 y metodo de inmunoensayo enzimatico altamente sensible.

Info

Publication number
ES2060621T3
ES2060621T3 ES88108837T ES88108837T ES2060621T3 ES 2060621 T3 ES2060621 T3 ES 2060621T3 ES 88108837 T ES88108837 T ES 88108837T ES 88108837 T ES88108837 T ES 88108837T ES 2060621 T3 ES2060621 T3 ES 2060621T3
Authority
ES
Spain
Prior art keywords
substance
highly sensitive
assay method
sensitive enzymatic
immuno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88108837T
Other languages
English (en)
Inventor
Mineo Niwa
Kouichi Tamura
Tsutomu Kaizu
Masakazu Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2060621T3 publication Critical patent/ES2060621T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1292—Gram-positive bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

LA INVENION SE REFIERE A UN ANTICIUERPO CAPAZ DE RECONOCER DETERMINANTES ANTIGENICOS LOCALIZADOS SOBRE LA SUSTANCIA FR-900506, A UN METODO DE INMUNOENSAYO DE ENZIMA ALTAMENTE SENSIBLE PARA LA SUSTANCIA FR-900506, QUE COMPRENDE INMOVILIZAR UN ANTICUERPO CAPAZ DE RECONOCER LOS DETERMINANTES ANTIGENICOS LOCALIZADOS SOBRE LA SUSTANCIA FR-900506, QUE PERMITE A DICHA SUSTANCIA CONTENIDA EN UNA MUESTRA Y A UNA SUSTANCIA FR-900506 MARCADA CON UNA ENZIMA REACCIONAR COMPETITIVAMENTE CON EL ANTICUERPO INMOVILIZADO Y DETECTAR LA SUSTANCIA MARCADA CON LA ENZIMA UNIDA AL ANTICUERPO INMOVILIZADO Y A UN KIT DE ENSAYO PARA DETECTAR LA SUSTANCIA FR-900506. LA INVENCION COMPRENDE TAMBIEN UN PROCESO PARA PREPARACION E UN ANTICUERPO MONOCLONAL QUE IMPLICA CULTIVAR UNA LINEA DE CELULAS DE HIBRIDOMA CAPAZ DE PRODUCIR ANTICUERPO DE LA SUSTANCIA FR-900506 Y AISLARLO DEL CALDO DE CULTIVO.
ES88108837T 1987-06-05 1988-06-02 Anticuerpos anti-sustancia fr-900506 y metodo de inmunoensayo enzimatico altamente sensible. Expired - Lifetime ES2060621T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14177687 1987-06-05

Publications (1)

Publication Number Publication Date
ES2060621T3 true ES2060621T3 (es) 1994-12-01

Family

ID=15299904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88108837T Expired - Lifetime ES2060621T3 (es) 1987-06-05 1988-06-02 Anticuerpos anti-sustancia fr-900506 y metodo de inmunoensayo enzimatico altamente sensible.

Country Status (6)

Country Link
US (1) US5532137A (es)
EP (1) EP0293892B1 (es)
AT (1) ATE98700T1 (es)
DE (1) DE3886265T2 (es)
DK (1) DK173938B1 (es)
ES (1) ES2060621T3 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504956A (ja) * 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
WO1994024568A1 (en) * 1993-04-20 1994-10-27 Abbott Laboratories Stable aqueous fk506 standards
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
GB9318612D0 (en) * 1993-09-08 1993-10-27 Sandoz Ltd An assay
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5635406A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies
US5650288A (en) * 1995-07-14 1997-07-22 Macfarlane; Gordon D. Immunophilin-bound immunosuppressant assay
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US7078495B1 (en) 1999-08-03 2006-07-18 Dade Behring Inc. Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
US7186518B2 (en) 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
US8022188B2 (en) 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
CA2673296C (en) 2006-12-29 2012-10-16 Abbott Laboratories Improved assay for immunosuppressant drugs
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
BRPI0722361B8 (pt) 2007-12-19 2021-07-27 Abbott Lab métodos para avaliar a concentração de um fármaco imunossupressor em uma amostra de sangue humano, composição de reagente de extração e kit de teste
US20110136253A1 (en) * 2009-12-08 2011-06-09 Salamone Salvatore J Irinotecan Immunoassay
US20110165699A1 (en) * 2009-12-08 2011-07-07 Salamone Salvatore J Irinotecan immunoassay
WO2012054639A2 (en) 2010-10-22 2012-04-26 T2 Biosystems, Inc. Nmr systems and methods for the rapid detection of analytes
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
WO2012067670A1 (en) * 2010-11-18 2012-05-24 Saladax Biomedical Inc. Irinotecan immunoassay
US9562271B2 (en) 2012-04-20 2017-02-07 T2 Biosystems, Inc. Compositions and methods for detection of Candida species
WO2017074703A1 (en) 2015-10-29 2017-05-04 Siemens Healthcare Diagnostics Inc. Sandwich assay for small molecules
WO2017127731A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
JP7319362B2 (ja) * 2018-11-02 2023-08-01 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド マクロフィリン結合医薬アッセイに使用するための結合競合剤およびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL62965A0 (en) * 1980-07-17 1981-07-31 Scripps Miles Lab Inc Monoclonal antibodies to drugs and theri production
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Also Published As

Publication number Publication date
EP0293892A3 (en) 1990-01-31
EP0293892A2 (en) 1988-12-07
DK173938B1 (da) 2002-02-25
DE3886265T2 (de) 1994-04-28
EP0293892B1 (en) 1993-12-15
DK305688A (da) 1988-12-06
DE3886265D1 (de) 1994-01-27
ATE98700T1 (de) 1994-01-15
US5532137A (en) 1996-07-02
DK305688D0 (da) 1988-06-03

Similar Documents

Publication Publication Date Title
ES2060621T3 (es) Anticuerpos anti-sustancia fr-900506 y metodo de inmunoensayo enzimatico altamente sensible.
DK0483194T3 (da) IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
ES2053785T3 (es) Estuche y metodo de dosificado inmunometrico aplicables a celulas enteras.
ES2124215T3 (es) Unos anticuerpos monoclonales al fiv y polipeptidos relacionados y su metodo de obtencion.
CN102262159B (zh) 用于检测生育相关人睾丸和附睾表达305种精子定位蛋白的方法
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
DK0755517T3 (da) Fremgangsmåde til detektion af tilstedeværelse af en Mycobacterium-art og et kit og antistoffer til anvendelse i denne
ES483606A1 (es) Metodo y su correspondiente kit de prueba para la deteccion-y-o determinacion de una inmunoglobulina especifica antige- nica.
DK577089D0 (da) Substratsammensaetning til alkalisk phosphatase og assayfremgangsmaade, hvori denne sammensaetning anvendes
ES8608685A1 (es) Procedimiento de preparar anticuerpos monoclonales y metodo de preparar reactivos para detectar canceres
ES8707114A1 (es) Procedimiento para la obtencion de un anticuerpo monoclonal anti-alfa-amilasa
KR940000870A (ko) β-N- 아세틸글루코사미니다제의 샌드위치 면역 측정법 및 그 측정법에 사용된 모노클론 항체
ES2056919T3 (es) Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana.
ES522722A1 (es) Procedimiento de inmunoanalisis para determinar propanolol en una muestra
ATE195955T1 (de) Nachweis, test und gewinnung von zusammensetzungen die ein taxanringskelett enthalten
DK484588A (da) Monoklonalt antistof, der genkender a-hanp, og reagens til immunoanalyse af a-hanp
ES8401129A1 (es) Procedimiento para aumentar la capacidad de ixodasa de apoglucosa para combinarse con dinucleotido de flavinadenina y sus derivados del mismo.
NO852058L (no) Fremgangsmaate og middel for bestemmelse av atl virus antistoffer.
Listek et al. Comment on “Monoclonal Antibody Discovery based on precise selection of single transgenic hybridomas with an On-Cell-Surface and Antigen-Specific Anchor”
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
DK1879029T3 (da) Immuneftervisningskit i forbindelse med neuroglobinenzym samt anvendelse heraf
JPS56118672A (en) Measuring method of antigen or antibody
JPS5386014A (en) Quantitative analysis of antigen and antibody
KR930701619A (ko) 인체 면역 결핍 바이러스의 gag 단백질 전구체 p55에 대한 단일클론 항체

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 293892

Country of ref document: ES